Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IDH inhibitors in AML

Courtney DiNardo, MD, MSCE, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the use of IDH inhibitors in acute myeloid leukemia (AML), which are approved in the relapsed setting for this indication and discusses future approaches using this class of agents. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

The content of VJHemOnc is intended for healthcare professionals